Search Results for "Sunitinib"

20:26 EDT 30th August 2016 | BioPortfolio

Matching Channels


Matching News

Sunitinib vs. Everolimus for Advanced Non–Clear-Cell Renal Cancer

Progression-free survival was longer with sunitinib in patients with papillary and unclassified histologies, but longer with everolimus in those with chromophobe histology.

Cabozantinib Improves PFS Over Sunitinib in Untreated Advanced RCC

A phase II trial found that cabozantinib offers significantly better progression-free survival over sunitinib in patients with untreated advanced RCC.

Exelixis’ Phase ll trial finds cabozantinib better than sunitinib in treating RCC

US-based biopharmaceutical company Exelixis has demonstrated improvement in progression-free survival (PFS) with cabozantinib, compared to sunitinib in patients with advanced intermediate or poor risk...

Sutent sunitinib: Phase III data

[Articles] Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): a double-blind, placebo-controlled, randomised, phase 3 trial

Adjuvant treatment with the VEGF receptor tyrosine kinase inhibitors sorafenib or sunitinib showed no survival benefit relative to placebo in a definitive phase 3 study. Furthermore, substantial treat...

Kidney cancer: Exosome transmission of sunitinib resistance

Kidney cancer: No advantage of adjuvant sunitinib or sorafenib

Kidney cancer: Power couple: reovirus meets sunitinib

Matching PubMed Articles

Sunitinib uptake inhibits platelet function in cancer patients.

Sunitinib is an oral tyrosine kinase inhibitor used for cancer treatment. Patients treated with sunitinib are at higher bleeding risk. As tyrosine kinases are essential for platelet signalling, the ef...

The microRNA signature of patients with sunitinib failure: regulation of UHRF1 pathways by microRNA-101 in renal cell carcinoma.

Molecular targeted therapy is a standard treatment for patients with advanced renal cell carcinoma (RCC). Sunitinib is one of the most common molecular-targeted drugs for metastatic RCC. Molecular mec...

Clinical activity of sunitinib rechallenge in metastatic renal cell carcinoma-Results of the REchallenge with SUnitinib in MEtastatic RCC (RESUME) Study.

To assess the efficacy and tolerability of sunitinib rechallenge in the third-line or later setting in patients with metastatic renal cell carcinoma (mRCC).

Sunitinib Induced Immune Thrombocytopenia.

Sunitinib is an oral tyrosine kinase inhibitor which prevents tumor growth and metastatic progression. It was approved for treatment of advanced renal cell cancer, gastrointestinal stromal tumor and a...

Tyrosine kinase inhibitor sunitinib therapy is effective in treatment of bone metastasis from cancer of unknown primary: Identification of clinical and immunohistochemical biomarkers predicting survival.

Bone metastasis from cancer of unknown primary (BMCUP) brings poor survival prognosis and its management remains controversial. Sunitinib (SUTENT) proved effective in many sorts of solid tumors but ha...

Search Whole site using Google

Quick Search
Advertisement Advertisement